Abstract
The list of therapeutically relevant biomarkers in NSCLC is continually expanding and hence molecular profiling is of paramount importance. Tissue availability and chance of rebiopsy is a major limitation in lung cancer and sequential single gene assays lead to tissue exhaustion and inadvertent delays in institution of therapy. We sought to compare the performance of targeted next-generation sequencing (NGS) panels with traditional assays and correlate the mutational landscape in an Indian NSCLC cohort.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
